NHERF1 PROTEIN EXPRESSION IN BREAST CANCER A Mangia*, I Suriano*, A Malfettone*, A Bellizzi*, O Popescu**, R Daprile**, B Stea*, G Simone** and A Paradiso*

Slides:



Advertisements
Similar presentations
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Advertisements

Immunohistochemistry ESE3 Immunohistochemistry. stained prostate tissue samples for ESE3 troubleshooted ESE3 antibody using the controls - no antibodies.
HISTOLOGICAL QUALITY CONTROL OF FROZEN SAMPLES USING MATCHING FFPE TISSUE – PRELIMINARY RESULTS OF OUR INSTITUTIONAL BIOBANK E. Mattioli, E. Foglia Manzillo,
Jihye Choi June. Introduction Hepatitis B virus -Four overlapping reading frames -S: the viral surface proteins -P: viral polymerase.
Cancer-stroma interactions: role of cancer-associated fibroblasts and mast cells in breast carcinogenesis A Malfettone 1, G Simone 2, R Rossi 3, C Salvatore.
Investigation Of Cell-Adhesion Molecules In Prostate Cancer Progression Abstract. Lakshana Sreenivasan 4,5, Edward Abril 4,5, Kathleen McDaniel 4,5, Raymond.
Slide Seminar Sami Shousha, MD, FRCPath Department of Histopathology, Charing Cross Hospital & Imperial College, London Amman, November 2013.
Pathology Journal Reading
Immunohistochemistry
Eva Compe´rat1, Fan Zhang1, Cedric Perrotin2, Thierry Molina1, Pierre Magdeleinat2,Beatrice Marmey1, Jean-Francois Re´gnard2, Josee Audouin1 and Saphie.
Estrogen and its receptors play an important role in breast carcinogenesis. In humans, there are two subtypes of estrogen receptors (ER), ER  and ER ,
 MicroRNAs (miRNAs) are a class of small RNA molecules, about ~21 nucleotide (nt) long.  MicroRNA are small non coding RNAs (ncRNAs) that regulate.
When mammalian cells are subjected to stress signals, oxygen deficiency, radiation, DNA damage, or Chemo- therapeutic drugs, p53 is activated, leading.
Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
Immunohistochemistry (IHC) Lab 11. IHC IHC refers to the process of detecting antigens in cells of a tissue section by exploiting the principle of antibodies.
The basics of immunohistochemistry. Principle Anigen (protein of interest) Primary antibody Secondary antibody.
Circulating tumor cells (CTCs) in blood of breast cancer patients: Cytological detection and technical characterization Enrica Bresaola, Mara Jo Miller,
Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.
Presented By: Lana Awad and Sebastian Lukjan. Motivation of research, why they did what they did…  Understand steps that cancer cells take to spread.
Na + /H + exchanger regulatory factor 1 (NHERF1) and angiogenesis in familial breast cancer A Mangia*, A Malfettone*, C Salvatore**, B Stea*, G Simone**
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes A.Ieni, A. Simone, G. Neri, V. Barresi, G. Giuffrè, B.
Introduction The effects of HER2 gene and receptor over- expression on breast cancer. Prognosis and treatment of HER2+ breast cancer. (See figure 1)
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
Characteristics of Cancer. Promotion (reversible) Initiation (irreversible) malignant metastases More mutations Progression (irreversible)
Survivin and XIAP expression in multiple pulmonal metastases from renal cell carcinoma (RCC) patients: results of tissue micro array (TMA) studies P. Schneider.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.
A103 : Normal tissues, more than single spot Specification : Specimen : formalin-fixed, paraffin-embedded 1.0mm diameter 54 different types of normal tissue.
 Antigen-antibody interactions Antigen Antibodies producedAntibodies binds antigen.
Gas: 2000 liters of methane gas released/day! Size : 6 tons 250kg food eaten every 100kg of elephant dung/day Gestation : 23 months Females give birth.
Lab #6: Immunohistochemistry (IHC)
EXPRESSION OF HER-2 CORRELATED PROTEINS IN ILEAL CARCINOIDS Azzoni C., Giordano G., Bottarelli L., Tamburini E., D’Adda T., Pizzi S., Rindi G., Bordi C.
INTRODUCTION & OBJECTIVES Introduction: The carcinogenesis of hepatocellular carcinoma (HCC) is a multifactorial, multistep and complex process. Its prognosis.
ICC Immunocytochemistry
Supplemental Figure 1. Specificity of CCL2 and Fsp1 immunostaining of breast tumor tissues. Sections of invasive ductal carcinoma were incubated with primary.
EXPRESSION OF ABERRANT p53 PROTEIN IN GASTRIC CANCER
W. Scott Campbell, MBA, PhD James R. Campbell, MD
An Extensive Tumor Array Analysis Supports Tumor Suppressive Role for Nucleophosmin in Breast Cancer  Piia-Riitta Karhemo, Antti Rivinoja, Johan Lundin,
Table 2. Association between histology grade, lymph node status,
Alvin Y. Liu, Martine P. Roudier, Lawrence D. True 
Visualization of tissue and plasma kallikreins and kinin B1 and B2 receptors in human lung carcinomas and mesothelioma Jessica Chee.
Breast cancer cutaneous metastases: implications of MUC1 and
Volume 22, Issue 6, Pages (December 2012)
detection using ECL kit
Matteo Centonze, Concetta Saponaro, Anita Mangia 
INTERNATIONAL CONFERENCE
Molecular Basis Of Cancer
UHRF1 is regulated by miR-9 in colorectal cancer
Volume 44, Issue 4, Pages (October 2003)
Volume 115, Issue 1, Pages (July 1998)
Volume 22, Issue 6, Pages (December 2012)
Volume 67, Issue 4, Pages (April 2005)
Dr Yve Zhang (Consultant, Cellular Pathology)
Christina I. Selinger, PhD, Wendy A
Immunohistochemistry
ASPP2 Regulates Epithelial Cell Polarity through the PAR Complex
Anna Maria Cesinaro, Gian Paolo Trentini, Dr. 
Genomewide profiling of chromatin accessibility in prostate cancer specimens Genomewide profiling of chromatin accessibility in prostate cancer specimens.
Molecular pathology of allergic disease
A, DEAR1 and SMAD3 immunohistochemical staining in human breast cancer tissues. A, DEAR1 and SMAD3 immunohistochemical staining in human breast cancer.
FAK overexpression in invasive human breast cancer and DCIS
(Handling and Evaluation of Breast Cancer Biopsy)
FAK overexpression in invasive human colon cancer and colon dysplasia.
SAF-1 expression in clinical breast cancer tissues.
Immunohistochemical staining for FOXO3a of breast cancer tumor tissues
In situ analysis of human breast tissue shows the down-regulation of Spry isoforms in breast cancer. In situ analysis of human breast tissue shows the.
Practical of Histopathology
A, TSG-6 staining in human prostate.
Vorozole treatment-associated changes in protein abundance of multiple antigens. Vorozole treatment-associated changes in protein abundance of multiple.
Presentation transcript:

NHERF1 PROTEIN EXPRESSION IN BREAST CANCER A Mangia*, I Suriano*, A Malfettone*, A Bellizzi*, O Popescu**, R Daprile**, B Stea*, G Simone** and A Paradiso* *Clinical Experimental Oncology Laboratory, National Cancer Institute-Bari ** Histopathology Unit National Cancer Institute-Bari

BACKGROUND  NHERF1 (Na + /H + exchanger regulator factor) is a PDZ domain containing protein that recruits membrane receptors/transporters and cytoplasmic signalling proteins into functional complexes. NHERF1 expression is altered in breast cancer but its effective role in mammary carcinogenesis remains undefined.  We further clarify the role of NHERF1 breast progression exploring the tissue distribution and cellular localization of NHERF1 protein in human normal tissue (NT), atypical ductal hyperplasia (ADH), carcinoma in situ (CIS), invasive carcinoma (IBC), synchronous metastatic lymph node and distant metastasis of a series of breast cancer.

MATERIALS AND METHODS According to pathological classification, the study was performed on: a) 35 ADH; b) 14 CIS and the surrounding non-cancerous tissues; c) 22 IBC from node negative patients (N0M0) and the surrounding non-cancerous tissues; d) 19 IBC, the surrounding non-cancerous tissues and synchronous metastatic lymph nodes from node positive patients (N1M0); e) 10 IBC, the surrounding non-cancerous tissues, synchronous metastatic lymph nodes and distant metastasis from patients with metastatic disease (N1M1).

Immunohistochemistry was performed on breast tissue specimens by utilizing standard procedure for sampling, fixation, paraffin inclusion and slides preparation. Histological sections of 4  m were incubated with rabbit polyclonal antibody EBP50, 1:150 dilution (PA1-090 Affinity Bioreagents, Golden, CO) overnight at 4°C. The bound antibody was visualized using a biotinylated secondary antibody, peroxidase-labelled streptavidin, and AEC substrate- chromogen (LSAB2 System-HRP;DakoCytomation). The slides were counterstained with H&E and mounted with permanent mounting media. Paraffin-embedded cells pellets from MCF-7 cell lines, expressing high levels of NHERF1, were used as positive controls. For negative controls, the primary antibody was omitted and replaced by PBS. Immunohistochemistry  Immunohistochemistry

Immunohistofluorescence studies were performed on 24 formalin-fixed tumor tissue sections selected among those with overexpressed HER2/neu (moAb, clone CB11 - Novocastra Laboratories Ltd, UK), scored 2+ and 3+. For antigen retrieval pretreatment, serial sections of 3  m were immersed in a 10 mM citrated buffer, pH 6.0, at 95°C, 40 min. Then, slides were washed in dH 2 O, treated 10 min with 0.2% BSA in PBS to block non specific protein binding, and incubated with NHERF1, 1:150 dilution (PA1-090 Affinity Bioreagents, Golden, CO) and HER2/neu antibody 1:40 dilution, overnight at 4°C in a humidified chamber. For negative controls, slide sections that were positive for staining were treated with 0.2% BSA instead of the primary antibody. Images were obtained on a BX40 microscope (Olympus) with a SenSys 1401E-Photometrics CCD camera. Immunohistofluorescence  Immunohistofluorescence

A NHERF1 immunopositivity was present mostly as apical membranous immunoreactivity, especially at the luminal aspects of morphologically normal cells (A) or as both cytoplasmic and membranous localizaton in ADH and CIS (B,C). RESULTS NHERF1 localization and expression in different compartment of breast tissue RESULTS NHERF1 localization and expression in different compartment of breast tissue C B

D E F NHERF1 positivity was present mostly as cytoplasmic staining in IBC (D) and methachronus distant metastases (E). In synchronous metastatic lymph node tissues (F) NHERF1 immunoreactivity was present exclusively as cytoplasmic localization. NHERF1 localization and expression in different compartments of breast tissue

Cellular distribution of NHERF1 in breast tissues  Significantly higher cytoplasmic-levels of the protein resulted in both synchronous metastatic lymph nodes and distant metastases with respect to the corresponding normal tissues (p= , p= respectively) and CIS (p=0.002, p=0.03 respectively).  In NT, ADH and CIS tissues, NHERF1 was present mainly in apical membrane with expression levels significantly higher than the cytoplasmic amount.  Notably, the cytoplasmic amount of NHERF1 detected in IBC tissues was significantly increased with respect to the corresponding cytoplasmic levels of the protein observed in NT and CIS tissues ( p=0.0001, p=0.007 respectively ).

Cytoplasmic accumulations of NHERF1 in paired samples of NT and CIS tissue Cytoplasmic accumulations of NHERF1 in paired samples of NT and IBC tissue The cytoplasmic NHERF1 expression levels in paired CIS and NT from 12 patients (fig A) and in paired IBC and NT from 44 patients (fig B), showed a heterogeneous behaviour with some cases increasing but other lowering NHERF1 expression levels in the different sites. AB

NHERF1 characteristics in tumour progression No significant difference in mean-levels of NHERF1 cytoplasmic expression was found when both synchronous metastatic lymph node either distant metastases were compared with the IBC tissues.

Intense NHERF1 staining was found at the apical surface of morphologically normal epithelial cells, while HER2/neu was found as basolateral and in intraepithelial junctions (A). This localization is present also in CIS (B). : Green signal : HER2/neu : Red signal: NHERF1 A B NHERF1 and HER2/neu co-localization

In IBC (A) and in synchronous metastatic lymph node (B), NHERF1 lost its exclusively apical localization in the tumor epithelial cells, becoming mostly cytosolic in no longer polarized cells of the tumor nests. A B : Green signal : HER2/neu : Red signal: NHERF1

In tumor cells from metachronous distant metastases NHERF1, still localized in the sub-membrane region, was found to be co- localized with HER2/neu, suggesting an important role of these two proteins in driving invasion and metastasis to distant tissue. In these metastatic samples large areas of NHERF1 nuclear localization were present, suggesting a role of NHERF1 also in trascription pathways necessary for this process. : Green signal : HER2/neu : Red signal: NHERF1

CONCLUSIONS  We suppose that breast cancerogenesis is characterized by an increased cytoplasmic expression of NHERF1 as the tumor progresses suggesting a role in this process. The switch from apical membrane to cytoplasmic expression is compatible with a dual role of NHERF1 as a tumor suppressor or tumor promoter dependent on its subcellular localization.  In invasive tumor and distant metastasis, the sub-membrane NHERF1, still present, is able to interact with HER2/neu, probably regulating its trafficking.  Their interaction could be of some relevance in the metastatization processes.

Dai JL, Wang L, Sahin AA, et al. NHERF (Na + /H + exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 2004; 23; Stemmer-Rachamimov, AO, Wiederhold, T, Nielsen, GP, et al. NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am. J. Pathol. 2001; 158; 57–62. Cardone RA, Bellizzi A, Mangia A, et al. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell. 2007; 18; Song J, J Bai, W Yang, EW Gabrielson, et al.Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer. Histopathology 2007; 51; BIBLIOGRAPHY